January 2013 NIDA-funded researchers have gathered evidence that brief interventions can help adolescents move away from drug use. In a clinical trial, middle and high school students markedly reduced their substance use following two 60-minute sessions that combined motivational interviewing and cognitive behavioral therapy.
March 2017 In two pilot clinical trials, buprenorphine helped participants reduce their illicit opioid use and injection drug use while awaiting admission to a methadone or buprenorphine treatment program. Researchers minimized the risks for improper use or diversion of the study medication by giving it to trial participants in a computerized, tamper-proof device that dispenses one dose each day.
July 2012 Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.
February 2014 California’s Proposition 36, which allows qualified drug offenders to enter substance use treatment rather than go to jail or prison, saved the state close to $100 million in its first year.
December 2010 Reports on the results of a clinical trial that tested the effectiveness of a cocaine vaccine designed as a therapy for cocaine abuse and plans underway for a new study of 300 patients to confirm these results.
March 2011 Examines results from a randomized clinical trial which found that treatment with a nicotine patch and nicotine lozenge together produced the greatest benefits in helping people quit smoking and remain abstinent.